NASDAQ:KRTX

Karuna Therapeutics Competitors

$118.45
+7.40 (+6.66 %)
(As of 04/14/2021 11:23 AM ET)
Add
Compare
Today's Range
$113.99
Now: $118.45
$118.45
50-Day Range
$112.02
MA: $119.72
$133.08
52-Week Range
$69.00
Now: $118.45
$146.97
Volume2,695 shs
Average Volume207,717 shs
Market Capitalization$3.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07

Competitors

Karuna Therapeutics (NASDAQ:KRTX) Vs. TEVA, BHC, RDY, MRVI, JAZZ, and UTHR

Should you be buying KRTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Karuna Therapeutics, including Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), Jazz Pharmaceuticals (JAZZ), and United Therapeutics (UTHR).

Teva Pharmaceutical Industries (NYSE:TEVA) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and Karuna Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.72$-998,000,000.00$2.314.80
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19

Karuna Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Teva Pharmaceutical Industries and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Karuna TherapeuticsN/A-13.91%-13.72%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Teva Pharmaceutical Industries and Karuna Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries19402.21
Karuna Therapeutics001103.00

Teva Pharmaceutical Industries presently has a consensus target price of $11.80, indicating a potential upside of 6.79%. Karuna Therapeutics has a consensus target price of $144.70, indicating a potential upside of 22.16%. Given Karuna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karuna Therapeutics is more favorable than Teva Pharmaceutical Industries.

Insider & Institutional Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Summary

Karuna Therapeutics beats Teva Pharmaceutical Industries on 8 of the 13 factors compared between the two stocks.

Karuna Therapeutics (NASDAQ:KRTX) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Karuna Therapeutics and Bausch Health Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karuna Therapeutics001103.00
Bausch Health Companies14702.50

Karuna Therapeutics presently has a consensus price target of $144.70, indicating a potential upside of 22.16%. Bausch Health Companies has a consensus price target of $32.5833, indicating a potential upside of 7.11%. Given Karuna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karuna Therapeutics is more favorable than Bausch Health Companies.

Profitability

This table compares Karuna Therapeutics and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karuna TherapeuticsN/A-13.91%-13.72%
Bausch Health Companies-23.92%173.20%4.21%

Institutional & Insider Ownership

74.8% of Karuna Therapeutics shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 18.1% of Karuna Therapeutics shares are owned by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Karuna Therapeutics and Bausch Health Companies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19
Bausch Health Companies$8.60 billion1.26$-1,788,000,000.00$4.436.88

Karuna Therapeutics has higher earnings, but lower revenue than Bausch Health Companies. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Karuna Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Summary

Karuna Therapeutics beats Bausch Health Companies on 8 of the 13 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Karuna Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.53$259 million$2.7922.63
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19

Dr. Reddy's Laboratories has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Dr. Reddy's Laboratories and Karuna Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
Karuna Therapeutics001103.00

Dr. Reddy's Laboratories presently has a consensus target price of $70.00, suggesting a potential upside of 10.88%. Karuna Therapeutics has a consensus target price of $144.70, suggesting a potential upside of 22.16%. Given Karuna Therapeutics' higher probable upside, analysts clearly believe Karuna Therapeutics is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Karuna TherapeuticsN/A-13.91%-13.72%

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Summary

Dr. Reddy's Laboratories beats Karuna Therapeutics on 7 of the 12 factors compared between the two stocks.

Karuna Therapeutics (NASDAQ:KRTX) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Karuna Therapeutics and Maravai LifeSciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19
Maravai LifeSciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Karuna Therapeutics and Maravai LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karuna Therapeutics001103.00
Maravai LifeSciences001003.00

Karuna Therapeutics presently has a consensus target price of $144.70, indicating a potential upside of 22.16%. Maravai LifeSciences has a consensus target price of $38.1250, indicating a potential upside of 4.14%. Given Karuna Therapeutics' higher probable upside, equities analysts plainly believe Karuna Therapeutics is more favorable than Maravai LifeSciences.

Institutional & Insider Ownership

74.8% of Karuna Therapeutics shares are held by institutional investors. 18.1% of Karuna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Karuna Therapeutics and Maravai LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karuna TherapeuticsN/A-13.91%-13.72%
Maravai LifeSciencesN/AN/AN/A

Summary

Karuna Therapeutics beats Maravai LifeSciences on 4 of the 6 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Karuna Therapeutics (NASDAQ:KRTX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Jazz Pharmaceuticals and Karuna Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Karuna Therapeutics001103.00

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 12.33%. Karuna Therapeutics has a consensus target price of $144.70, indicating a potential upside of 22.16%. Given Karuna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karuna Therapeutics is more favorable than Jazz Pharmaceuticals.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Karuna Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.33$523.37 million$14.6011.38
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19

Jazz Pharmaceuticals has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jazz Pharmaceuticals and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Karuna TherapeuticsN/A-13.91%-13.72%

Summary

Jazz Pharmaceuticals beats Karuna Therapeutics on 9 of the 13 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Karuna Therapeutics (NASDAQ:KRTX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of current ratings and target prices for United Therapeutics and Karuna Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Karuna Therapeutics001103.00

United Therapeutics currently has a consensus target price of $219.5714, suggesting a potential upside of 8.74%. Karuna Therapeutics has a consensus target price of $144.70, suggesting a potential upside of 22.16%. Given Karuna Therapeutics' higher probable upside, analysts clearly believe Karuna Therapeutics is more favorable than United Therapeutics.

Profitability

This table compares United Therapeutics and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Karuna TherapeuticsN/A-13.91%-13.72%

Institutional & Insider Ownership

90.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 10.9% of United Therapeutics shares are owned by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Valuation & Earnings

This table compares United Therapeutics and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.21$-104,500,000.00($2.39)-84.49
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.19

Karuna Therapeutics has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Karuna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

United Therapeutics beats Karuna Therapeutics on 7 of the 12 factors compared between the two stocks.


Karuna Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$11.08+2.9%$11.75 billion$16.89 billion-3.01Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.48+2.2%$10.60 billion$8.60 billion-5.59
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$63.13+0.7%$10.43 billion$2.32 billion52.17News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.61+2.5%$9.66 billionN/A0.00Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$166.19+1.7%$9.20 billion$2.16 billion52.43Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.7$201.92+1.3%$8.88 billion$1.45 billion19.10Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$57.96+5.8%$8.13 billion$40.56 million-17.00Analyst Report
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$164.64+2.9%$8.09 billion$3.34 million-21.38
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$110.45+3.5%$7.14 billion$103.71 million-25.16Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.39+0.2%$6.83 billion$311.33 million-126.97Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$126.07+1.0%$6.71 billion$14.98 million-15.36
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.14+4.8%$6.64 billion$87.99 million-79.93Unusual Options Activity
News Coverage
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.85+2.6%$6.28 billion$150,000.00-21.63
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.46+3.2%$5.79 billion$1.12 billion88.46
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$74.06+5.5%$5.56 billion$380.83 million-9.47
Allakos logo
ALLK
Allakos
1.7$108.04+3.3%$5.55 billionN/A-39.43
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$97.94+5.0%$5.39 billion$66.51 million18.07Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.62+1.2%$5.36 billion$4.84 billion-676.89
Schrödinger logo
SDGR
Schrödinger
1.5$78.55+3.8%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$81.95+4.5%$5.13 billion$1.00 billion-12.42Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$54.08+5.8%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$76.36+4.7%$4.52 billionN/A-6.22Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.45+0.6%$4.31 billion$204.89 million-36.81
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.17+5.6%$4.20 billion$6.87 million-7.36Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$68.56+3.2%$4.01 billion$806.43 million-9.71Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.53+3.7%$3.88 billion$1.11 billion24.29Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$77.03+2.9%$3.66 billionN/A-21.95Analyst Report
News Coverage
Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.33+4.2%$3.62 billion$117.91 million-11.02Gap Down
I-Mab logo
IMAB
I-Mab
1.4$54.35+8.7%$3.57 billion$4.31 million-1.88Increase in Short Interest
Gap Down
LEGN
Legend Biotech
1.2$27.13+2.5%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.60+4.6%$3.41 billion$114.62 million-7.90Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.79+5.7%$3.40 billionN/A-6.04
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$49.14+3.7%$3.33 billion$306.98 million-7.03
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.71+5.1%$3.30 billion$339.08 million-12.62Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.04+3.8%$3.29 billion$36.13 million-73.19Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.21+4.6%$3.27 billion$136.47 million-12.77
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.83+2.7%$3.13 billion$26.52 million-7.83
Alkermes logo
ALKS
Alkermes
1.2$19.59+3.7%$3.00 billion$1.17 billion-42.59
Arvinas logo
ARVN
Arvinas
1.5$64.73+5.2%$3.00 billion$42.98 million-25.29Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$70.44+3.1%$2.99 billion$421.03 million24.80Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.88+2.3%$2.94 billion$80.43 million108.96Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.52+1.5%$2.77 billion$644.77 million-10.49
OPKO Health logo
OPK
OPKO Health
1.9$4.24+2.6%$2.77 billion$901.90 million-23.55
Organogenesis logo
ORGO
Organogenesis
1.0$21.64+2.5%$2.70 billion$260.98 million-360.67
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.80+2.3%$2.61 billion$306.49 million25.62
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$45.02+6.6%$2.60 billionN/A-24.74
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.52+4.6%$2.51 billion$60,000.00-10.10
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$46.46+6.5%$2.50 billion$25 million-9.29
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.43+5.3%$2.50 billion$2.11 million-9.18Analyst Report
News Coverage
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.